Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
Express Scripts
Boehringer Ingelheim
Medtronic
Merck

Last Updated: October 15, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Sotrastaurin

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Sotrastaurin: Patents, clinical trial progress, indications

Sotrastaurin is an investigational drug.

There have been 6 clinical trials for Sotrastaurin. The most recent clinical trial was a Phase 2 trial, which was initiated on April 1st 2010.

The most common disease conditions in clinical trials are Uveal Neoplasms, Melanoma, and Lymphoma, Mantle-Cell. The leading clinical trial sponsors are Novartis Pharmaceuticals, Array BioPharma, and James Blachly.

There are eighteen US patents protecting this investigational drug and two hundred and forty-seven international patents.

Recent Clinical Trials for Sotrastaurin
TitleSponsorPhase
Trial of AEB071 in Combination With BYL719 in Patients With MelanomaRichard D. CarvajalPhase 1
A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal MelanomaArray BioPharmaPhase 1/Phase 2
Efficacy, Safety, Tolerability, Pharmacokinetics of Sotrastaurin-tacrolimus vs. Mycophenolic Acid-tacrolimus in de Novo Liver Transplant PatientsNovartis PharmaceuticalsPhase 2

See all Sotrastaurin clinical trials

Clinical Trial Summary for Sotrastaurin

Top disease conditions for Sotrastaurin
Top clinical trial sponsors for Sotrastaurin

See all Sotrastaurin clinical trials

US Patents for Sotrastaurin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Sotrastaurin   See Pricing Stem cell modulation II University of Canberra (Bruce, Australian Capital Territory, AU)   See Pricing
Sotrastaurin   See Pricing Indolylmaleimide derivatives Novartis AG (Basel, CH)   See Pricing
Sotrastaurin   See Pricing Indolylmaleimide derivatives Novartis AG (Basel, CH)   See Pricing
Sotrastaurin   See Pricing Indolylmaleimide derivatives   See Pricing
Sotrastaurin   See Pricing Indolylmaleimide derivatives   See Pricing
Sotrastaurin   See Pricing Drug monitoring assay Novartis AG (Basel, CH)   See Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Sotrastaurin

Drugname Country Document Number Estimated Expiration Related US Patent
Sotrastaurin Australia 2014324092 2033-09-18   See Pricing
Sotrastaurin Canada 2923765 2033-09-18   See Pricing
Sotrastaurin China 105764513 2033-09-18   See Pricing
Sotrastaurin European Patent Office 3046560 2033-09-18   See Pricing
Sotrastaurin Japan 2016537400 2033-09-18   See Pricing
Sotrastaurin Singapore 11201601408P 2033-09-18   See Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
McKesson
Dow
Mallinckrodt
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.